AbstractBackgroundThe high recurrence rate after nonsurgical treatment of keloid is a major challenge for clinicians. Although there are many existing treatment options, how to optimize and upgrade the existing options and make a reasonable combination of utilization is our concern. The aim of this study is to provide a comprehensive non‐surgical treatment for keloid—cocktail therapy.MethodsAccording to the different changes of keloid with treatment, the treatment was divided into four stages, and different treatment schemes were adopted for each stage. The incidence of side effects of keloid at each stage and the effective rate and cure rate 16 months after the end of treatment were analyzed.ResultsAll patients completed this study on time, and were followed up 16 months after the end of treatment, the treatment effective rate was 100%, and the cure rate was up to 92.8%.ConclusionCocktail therapy can achieve a higher cure rate of keloid, and is worthy of clinical promotion.

More from our Archive

• DOI: 10.1093/bjd/ljad072 2023

  Malignancy risk in patients with atopic dermatitis: a population-based cohort study

  Joy Wan, Daniel B Shin, Maha N Syed, Katrina Abuabara, Adina R Lemeshow, Zelma C Chiesa Fuxench, Joel M Gelfand

• DOI: 10.1111/myc.13626 2023

  <i>Candida auris</i> from colonisation to candidemia: A four‐year study

  Juan Vicente Mulet Bayona, Nuria Tormo Palop, Carme Salvador García, María del Remedio Guna Serrano, Concepción Gimeno Cardona

• DOI: 10.1111/jocd.15872 2023

  Efficacy of combined treatment with human adipose tissue stem cell‐derived exosome‐containing solution and microneedling for facial skin aging: A 12‐week prospective, randomized, split‐face study

  Gyeong‐Hun Park, Hyuck Hoon Kwon, Joon Seok, Steven Hoseong Yang, Joon Lee, Byung Chul Park, Eun Shin, Kui Young Park

• DOI: 10.1093/bjd/ljad240 2023

  Safety and efficacy of amlitelimab, a fully human nondepleting, noncytotoxic anti-OX40 ligand monoclonal antibody, in atopic dermatitis: results of a phase IIa randomized placebo-controlled trial

  Stephan Weidinger, Thomas Bieber, Michael J Cork, Adam Reich, Rosamund Wilson, Sonia Quaratino, Marisa Stebegg, Nuala Brennan, Sally Gilbert, John T O’Malley, Ben Porter-Brown

• DOI: 10.1111/iwj.14311 2023

  Preclinical study of diabetic foot ulcers: From pathogenesis to vivo/vitro models and clinical therapeutic transformation

  Yuqing Du, Jie Wang, Weijing Fan, Renyan Huang, Hongfei Wang, Guobin Liu

• DOI: 10.1001/jamadermatol.2023.2008 2023

  Understanding Discordant Perceptions of Disease Severity Between Physicians and Patients With Eczema and Psoriasis Using Structural Equation Modeling

  Valencia Long, Zhaojin Chen, Ruochen Du, Yiong Huak Chan, Yik Weng Yew, Hazel H. Oon, Steven Thng, Nur Qasrina Binte Iskandar Lim, Chris Tan, Nisha Suyien Chandran, Jose M. Valderas, Phillip Phan, Ellie Choi

• DOI: 10.1093/bjd/ljad224 2023

  Has the time come to assess small-molecule/biologic drug combinations for the management of moderate-to-severe hidradenitis suppurativa?

  Carlo Alberto Maronese, John R Ingram, Angelo V Marzano

• DOI: 10.1093/sexmed/qfad030 2023

  Self-reported reasons for having difficulty reaching orgasm in men with diverse etiologies

  David L Rowland, Sarah Padilla, Zsuzsanna Kӧvi, Krisztina Hevesi

• DOI: 10.1093/ced/llad227 2023

  ChatGPT and dermatology: friends or foes?

  Luca Potestio, Fabrizio Martora, Alessia Villani, Angelo Ruggiero, Massimiliano Scalvenzi, Matteo Megna

• DOI: 10.1111/pde.15378 2023

  Efficacy and safety of ritlecitinib in adolescents with alopecia areata: Results from the <scp>ALLEGRO</scp> phase 2b/3 randomized, double‐blind, placebo‐controlled trial

  Maria Hordinsky, Adelaide A. Hebert, Melinda Gooderham, Ohsang Kwon, Nikolay Murashkin, Hong Fang, Kazutoshi Harada, Ernest Law, Dalia Wajsbrot, Liza Takiya, Samuel H. Zwillich, Robert Wolk, Helen Tran